Companies › Shanghai Xinzhi BioMed
3 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Hematology, Other; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BBM-H803 AAV vector expressing human factor VIII transgene | F8 | Phase 2 | Hemophilia A | May 2027 |
| BBM-H901 Adeno-associated virus (AAV) vector containing human factor IX (hFIX) transgene for gene t | F9 | Phase 2 | Hemophilia B | Jun 2028 |
| BBM-P002 AAV-based gene therapy delivering therapeutic gene cassette into putamen | – | Phase 1 | PD | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06111638 | BBM-H803 | Phase 2 | Hemophilia A | Hematology | May 2027 |
| NCT07195825 | BBM-P002 | Phase 1 | PD | Other | Dec 2027 |
| NCT05203679 | BBM-H901 | Phase 2 | Hemophilia B | Hematology | Jun 2028 |
CSL Behring Pfizer Roche Biocad BioMarin Pharmaceutical IntraBio Baxalta now part of Shire Regeneron Pharmaceuticals Swedish Orphan Biovitrum Sinocelltech
Genetix Biotherapeutics Minovia Therapeutics Juventas Cell Therapy Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.